We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
Read MoreHide Full Article
McKesson Corporation (MCK - Free Report) recently extended its relationship with Genpact Limited (G - Free Report) . The extension is aimed at bringing continued efficiency and automation capabilities to McKesson’s finance operations, utilizing automation and AI solutions.
The latest development is expected to significantly solidify McKesson’s foothold in the digital finance operating model optimization space on a global scale.
Rationale Behind the Extension
The extension builds on a long-standing association of simplifying and standardizing McKesson’s finance processes, leveraging its operational excellence and enterprise strategy roadmap, combined with Genpact’s process expertise. The companies have delivered digitally-enabled automation and other advanced technologies to drive greater effectiveness and efficiencies in McKesson’s finance processes.
With the latest extension, the partnership is expected to focus on advancing the operating model, scaling operating capabilities with digital initiatives and evolving customer-centric models.
Per McKesson’s management, the partnership with Genpact, in combination with other finance operating initiatives, will likely accelerate its multi-year strategic growth initiative and contribute to a significant reduction in the cost of finance operations. It is also expected to better position McKesson to meet the needs of the healthcare industry.
Genpact’s management believes that rapid changes and disruption have highlighted ongoing cost pressures, data management challenges and the need for agility. This has necessitated McKesson to continue to adapt its operating models.
Industry Prospects
Per a report by Precedence Research, the global digital health market was estimated to be $262.63 billion in 2022 and is anticipated to reach $939.54 billion by 2032 at a CAGR of 13.1%. Factors like the increasing penetration of smartphones, the rising availability of smartphone applications related to health and fitness and the growing adoption of telehealth are expected to drive the market.
Given the market potential, the recent extension of the tie-up is expected to boost McKesson’s position in the niche space.
Recent Developments
This month, McKesson announced that its independent specialty pharmacy specializing in oncology and rare disease areas, Biologics by McKesson, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA (quizartinib).
The same month, McKesson reported its first-quarter fiscal 2024 results, wherein it reported a solid uptick in its overall top line and bottom line. Robust performances by its U.S. Pharmaceutical, Prescription Technology Solutions and Medical-Surgical Solutions segments were also seen.
In June, McKesson launched its curated private brand of over-the-counter (OTC) health and wellness products, Foster & Thrive. The launch, expected to unify the company’s private brand portfolio, would consolidate Health Mart and Sunmark branded OTC products.
Price Performance
Shares of the company have gained 16.9% in the past year compared with the industry’s 10.4% rise and the S&P 500's 3.4% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, McKesson carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the broader medical space are Patterson Companies, Inc. (PDCO - Free Report) and HealthEquity, Inc. (HQY - Free Report) .
Patterson Companies, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 9.2%. PDCO’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 4.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Patterson Companies has gained 13.3% compared with the industry’s 10.4% rise over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 9.1%.
HealthEquity has gained 11.4% against the industry’s 16.3% decline over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
McKesson Corporation (MCK - Free Report) recently extended its relationship with Genpact Limited (G - Free Report) . The extension is aimed at bringing continued efficiency and automation capabilities to McKesson’s finance operations, utilizing automation and AI solutions.
The latest development is expected to significantly solidify McKesson’s foothold in the digital finance operating model optimization space on a global scale.
Rationale Behind the Extension
The extension builds on a long-standing association of simplifying and standardizing McKesson’s finance processes, leveraging its operational excellence and enterprise strategy roadmap, combined with Genpact’s process expertise. The companies have delivered digitally-enabled automation and other advanced technologies to drive greater effectiveness and efficiencies in McKesson’s finance processes.
With the latest extension, the partnership is expected to focus on advancing the operating model, scaling operating capabilities with digital initiatives and evolving customer-centric models.
Per McKesson’s management, the partnership with Genpact, in combination with other finance operating initiatives, will likely accelerate its multi-year strategic growth initiative and contribute to a significant reduction in the cost of finance operations. It is also expected to better position McKesson to meet the needs of the healthcare industry.
Genpact’s management believes that rapid changes and disruption have highlighted ongoing cost pressures, data management challenges and the need for agility. This has necessitated McKesson to continue to adapt its operating models.
Industry Prospects
Per a report by Precedence Research, the global digital health market was estimated to be $262.63 billion in 2022 and is anticipated to reach $939.54 billion by 2032 at a CAGR of 13.1%. Factors like the increasing penetration of smartphones, the rising availability of smartphone applications related to health and fitness and the growing adoption of telehealth are expected to drive the market.
Given the market potential, the recent extension of the tie-up is expected to boost McKesson’s position in the niche space.
Recent Developments
This month, McKesson announced that its independent specialty pharmacy specializing in oncology and rare disease areas, Biologics by McKesson, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA (quizartinib).
The same month, McKesson reported its first-quarter fiscal 2024 results, wherein it reported a solid uptick in its overall top line and bottom line. Robust performances by its U.S. Pharmaceutical, Prescription Technology Solutions and Medical-Surgical Solutions segments were also seen.
In June, McKesson launched its curated private brand of over-the-counter (OTC) health and wellness products, Foster & Thrive. The launch, expected to unify the company’s private brand portfolio, would consolidate Health Mart and Sunmark branded OTC products.
Price Performance
Shares of the company have gained 16.9% in the past year compared with the industry’s 10.4% rise and the S&P 500's 3.4% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, McKesson carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the broader medical space are Patterson Companies, Inc. (PDCO - Free Report) and HealthEquity, Inc. (HQY - Free Report) .
Patterson Companies, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 9.2%. PDCO’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 4.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Patterson Companies has gained 13.3% compared with the industry’s 10.4% rise over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 9.1%.
HealthEquity has gained 11.4% against the industry’s 16.3% decline over the past year.